ALPN News and Press, Alpine Immune Sciences Inc. From 12/11/20

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that Natasha A. Hernday has joined Alpine’s Board of Directors. Ms. Hernday bri...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that members of the Alpine senior leadership team will participate in an analyst-led f...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week aheadThe week ahead will see investors once again weigh the brightening prospects for COVID-19 vaccines against a surging pand...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will participate in a fireside chat at the Piper Sandler 32nd Annual Virtua...

Alpine Immune Sciences, Inc. (ALPN) Q3 2020 Earnings Conference Call November 12, 2020 04:30 PM ET Company Participants Laurence Watts - Investor Relations Mitchell Gold - Chairman & Chief Executive Officer Stanford Peng - President & Head of Research & Development Paul Rickey - C...

Alpine Immune Sciences (ALPN): Q3 GAAP EPS of -$0.28 misses by $0.05.Revenue of $1.91M (+558.6% Y/Y) misses by $14.17M.Press Release For further details see: Alpine Immune Sciences EPS misses by $0.05, misses on revenue

- Conference call and webcast today at 4:30 p.m. ET - Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune / inflammatory diseases, today provided a corporate update a...

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will release third quarter 2020 financial results on Thursday, November 12,...

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summi...